Procedure Codes Payable As an Inpatient Service When Delivered In
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Microsurgery: Free Tissue Transfer and Replantation
MICROSURGERY: FREE TISSUE TRANSFER AND REPLANTATION John R Griffin MD and James F Thornton MD HISTORY In 1964 Nakayama and associates15 reported In the late 1890s and early 1900s surgeons began what is most likely the first clinical series of free- approximating blood vessels, both in laboratory ani- tissue microsurgical transfers. The authors brought mals and human patients, without the aid of magni- vascularized intestinal segments to the neck for cer- fication.1,2 In 1902 Alexis Carrel3 described the vical esophageal reconstruction in 21 patients. The technique of triangulation for blood vessel anasto- intestinal segments were attached by direct microvas- mosis and advocated end-to-side anastomosis for cular anastomoses in vessels 3–4mm diam. Sixteen blood vessels of disparate size. Nylen4 first used a patients had a functional esophagus on follow-up of monocular operating microscope for human ear- at least 1y. drum surgery in 1921. Soon after, his chief, Two separate articles in the mid-1960s described Holmgren, used a stereoscopic microscope for the successful experimental replantation of rabbit otolaryngologic procedures.5 ears and rhesus monkey digits.16,17 Komatsu and 18 In 1960 Jacobson and coworkers,6 working with Tamai used a surgical microscope to do the first laboratory animals, reported microsurgical anasto- successful replantation of a completely amputated moses with 100% patency in carotid arteries as digit in 1968. That same year Krizek and associ- 19 small as 1.4mm diameter. In 1965 Jacobson7 was ates reported the first successful series of experi- able to suture vessels 1mm diam with 100% patency mental free-flap transfers in a dog model. -
Ureterolysis.Pdf
Information about your procedure from The British Association of Urological Surgeons (BAUS) This leaflet contains evidence-based information about your proposed urological procedure. We have consulted specialist surgeons during its preparation, so that it represents best practice in UK urology. You should use it in addition to any advice already given to you. To view the online version of this leaflet, type the text below into your web browser: http://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/Ureterolysis.pdf Key Points • Retroperitoneal fibrosis (RPF), also known as chronic periaortitis, forms at the back of your abdominal (tummy) cavity and can block your ureters (the tubes that carry urine from your kidneys to your bladder) • Ureterolysis is used to free your ureters from the blockage caused by the RPF • In most patients, the procedure involves open surgery through a long incision in your abdomen (tummy) but it can sometimes be done by laparoscopic (keyhole) surgery • To prevent further obstruction, we wrap your ureters in omentum (the fatty envelope inside your abdomen) or in a synthetic material • The procedure is usually reserved for patients in whom medical treatment has been unsuccessful • Care of patients with RPF is multi-disciplinary with physicians, expert surgeons and other specialists collaborating in your care What does this procedure involve? Freeing your ureters from scar tissue at the back of your abdomen to relieve the blockage and restore urine drainage from your kidneys. To prevent recurrence, we wrap your ureters in omentum (a sheet of fatty tissue found in your abdomen); if your omentum has been removed or is too small to use, we may wrap the ureters in a synthetic material. -
Robot-Assisted Laparoscopic Ureterolysis: Case Report and Literature Review of the Minimally Invasive Surgical Approach Ste´Fanie A
CASE REPORT Robot-Assisted Laparoscopic Ureterolysis: Case Report and Literature Review of the Minimally Invasive Surgical Approach Ste´fanie A. Seixas-Mikelus, MD, Susan J. Marshall, MD, D. Dawon Stephens, DO, Aaron Blumenfeld, MD, Eric D. Arnone, BA, Khurshid A. Guru, MD ABSTRACT INTRODUCTION Objectives: To evaluate our case of robot-assisted ureter- Ureteral obstruction secondary to extrinsic compression re- olysis (RU), describe our surgical technique, and review sults from both benign and malignant processes. Retroperi- the literature on minimally invasive ureterolysis. toneal fibrosis (RPF) and ureteral endometriosis (UE) are 2 uncommon conditions that cause ureteral obstruction.1–25 Methods: One patient managed with robot-assisted ure- terolysis for idiopathic retroperitoneal fibrosis was identi- First described in 1905 by Albarran and then by Ormond fied. The chart was analyzed for demographics, operative in 1948, RPF is a chronic inflammatory process character- parameters, and immediate postoperative outcome. The ized by deposition of dense fibrous tissue within the surgical technique was assessed and modified. Lastly, a retroperitoneum.26–28 Possible causes of RPF include med- review of the published literature on ureterolysis managed ications, infections, malignancy, inflammatory conditions, with minimally invasive surgery was performed. trauma, prior surgeries, and radiation therapy. About two- thirds of cases are considered idiopathic.10,25 Results: One patient underwent robot-assisted ureteroly- sis at our institution in 2 separate settings. Operative time Endometriosis, defined by the ectopic presence of endo- (OR) decreased from 279 minutes to 191 minutes. Esti- metrium, is another entity that can cause ureteral obstruc- mated blood loss (EBL) was less than 50mL. The patient tion. -
Code Procedure Cpt Price University Physicians Group
UNIVERSITY PHYSICIANS GROUP (UPG) PRICES OF PROVIDER SERVICES CODE PROCEDURE MOD CPT PRICE 0001A IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 1ST DOSE 0001A $40.00 0002A IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 2ND DOSE 0002A $40.00 0011A IMM ADMN SARSCOV2 100 MCG/0.5 ML 1ST DOSE 0011A $40.00 0012A IMM ADMN SARSCOV2 100 MCG/0.5 ML 2ND DOSE 0012A $40.00 0021A IMM ADMN SARSCOV2 5X1010 VP/0.5 ML 1ST DOSE 0021A $40.00 0022A IMM ADMN SARSCOV2 5X1010 VP/0.5 ML 2ND DOSE 0022A $40.00 0031A IMM ADMN SARSCOV2 AD26 5X10^10 VP/0.5 ML 1 DOSE 0031A $40.00 0042T CEREBRAL PERFUS ANALYSIS, CT W/CONTRAST 0042T $954.00 0054T BONE SURGERY USING COMPUTER ASSIST, FLURO GUIDED 0054T $640.00 0055T BONE SURGERY USING COMPUTER ASSIST, CT/ MRI GUIDED 0055T $1,188.00 0071T U/S LEIOMYOMATA ABLATE <200 CC 0071T $2,500.00 0075T 0075T PR TCAT PLMT XTRC VRT CRTD STENT RS&I PRQ 1ST VSL 26 26 $2,208.00 0126T CAROTID INT-MEDIA THICKNESS EVAL FOR ATHERSCLER 0126T $55.00 0159T 0159T COMPUTER AIDED BREAST MRI 26 26 $314.00 PR RECTAL TUMOR EXCISION, TRANSANAL ENDOSCOPIC 0184T MICROSURGICAL, FULL THICK 0184T $2,315.00 0191T PR ANT SEGMENT INSERTION DRAINAGE W/O RESERVOIR INT 0191T $2,396.00 01967 ANESTH, NEURAXIAL LABOR, PLAN VAG DEL 01967 $2,500.00 01996 PR DAILY MGMT,EPIDUR/SUBARACH CONT DRUG ADM 01996 $285.00 PR PERQ SAC AGMNTJ UNI W/WO BALO/MCHNL DEV 1/> 0200T NDL 0200T $5,106.00 PR PERQ SAC AGMNTJ BI W/WO BALO/MCHNL DEV 2/> 0201T NDLS 0201T $9,446.00 PR INJECT PLATELET RICH PLASMA W/IMG 0232T HARVEST/PREPARATOIN 0232T $1,509.00 0234T PR TRANSLUMINAL PERIPHERAL ATHERECTOMY, RENAL -
Psi Technical Specs V31.Pdf
AHRQ Quality Indicators Patient Safety Indicators: Technical Specifications Department of Health and Human Services Agency for Healthcare Research and Quality http://www.qualityindicators.ahrq.gov March 2003 Version 3.1 (March 12, 2007) AHRQ Quality Indicators Web Site: http://www.qualityindicators.ahrq.gov Table of Contents About the Patient Safety Indicators ............................................................................................................... 1 Patient Safety Indicators – Detailed Definitions ............................................................................................ 3 Complications of Anesthesia (PSI 1) ............................................................................................................ 3 Death in Low-Mortality DRGs (PSI 2) ........................................................................................................... 5 Decubitus Ulcer (PSI 3) ................................................................................................................................. 7 Failure to Rescue (PSI 4) .............................................................................................................................. 9 Foreign Body Left during Procedure, Secondary Diagnosis Field (PSI 5 and 21)...................................... 17 Iatrogenic Pneumothorax, Secondary Diagnosis Field (PSI 6 and 22)....................................................... 18 Selected Infections Due to Medical Care, Secondary Diagnosis Field (PSI 7 and 23) ............................. -
Contd... Supplementary Table 1: Contd
Supplementary Table1: Illustrates the main studies with ureteral endometriosis and their characteristics Author/year Journal Type of Number of Mean Ureteral Histological Management, n (%) study cases (n) age localization, n (%) type, n (%) Huang et al./2017 J Obstet RS 46 37.07 26 (56.5%) left, 22 (47.8%) 11 ureterolysis (23.9%), 28 (60.9%) Gynaecol Res 16 (34.8%) right, intrinsic, ureteroneocystostomy, 4 (8.7%) 4 (8.7%) bilateral 24 (52.2%) end‑to‑end ureteral anastomosis, extrinsic 3 (6.5%) nephrectomy Freire et al./2017 Urology RS 17 38 35.7% left, 14.3% 14.3% extrinsic, 7 distal ureterectomy, right, 10.7% bilateral 14.3% intrinsic 5 distal ureterectomy, and reimplantation (4 Lich‑Gregoir and 1 Lich‑Gregoir with psoas hitch), 3 ureteroureterostomy, 2 laparoscopic nephrectomy Kanno et al./2017 The Journal CR 1 25 100% right NR Laparoscopic segmental ureteral of Minimally resection and submucosal Invasive tunneling ureteroneocystostomy Gynecology with a psoas hitch and Boari flap Darwish et al./2017 J Minim RS 42 34.8 8 (19%) bilateral, 54.5% intrinsic 78% ureterolysis, 8% ureteral Invasive 17 (40.5%) right, resection followed by Gynecol 17 (40.5%) left end‑to‑end anastomosis, 14% ureteral resection and ureteroneocysostomy Alves et al./2017 J Minim RS 198 NR 7 (25%) left, 9 (32.1%) 76.9% intrinsic 100% ureterolysis, 6.06% Invasive right, 12 (42.9%) ureteral resection followed by Gynecol bilateral end‑to‑end anastomosis, 1 (0.5%) ureteroneocystostomy with Boari flap Abo et al./2016 Journal de RS 13 36 NR NR 11 (84.7%) advanced ureterolysis -
Urological Complications in Renal Transplantation
Henry Ford Hospital Medical Journal Manuscript 2015 Urological Complications in Renal Transplantation Riad N. Farah Richard Klugo Thomas Mertz Joseph C. Cerny Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Henry Ford Hosp Med Journal Vol 26, No 3, 1978 Urological Complications in Renal Transplantation Riad N. Farah, MD,* Richard Klugo, MD,* Thomas Mertz, MD,* and Joseph C. Cerny, MD' There were 116 renal transplants performed on 108 patients RAFT survival after renal transplantation depends upon over a five-year period at Henry Ford Hospital with three the vascular and urinary anastomosis as well as control of major urological complications. The rate of 2.6% compares graft rejection. Numerous factors contribute to good results favorably with that reported in other series. Careful pre in transplantation, among which are immediate function of operative urological evaluation together with technically the homograft, high degree of histocompatibility, the avoid precise ureteroneocystostomy are factors that minimize the ance of excessive immunosuppression, and minimal wound incidence of urological complications. and urological complications. There have been several reportsof urological complications following renal transplantation (See Table). Complication rates as high as 25.7%' have been reported with ureteropyelostomy, while the rates for ureteroneocystos tomy range from 15%^ to less than 1%.' In our review of 116 renal transplants we found three urological complications (2.6%). This rate compares favorably wfth that reported in earlier series and underscores the importance ofthe urolo gist in the work-up and management of the transplant recipient. -
Icd-9-Cm (2010)
ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular -
1 Annex 2. AHRQ ICD-9 Procedure Codes 0044 PROC-VESSEL
Annex 2. AHRQ ICD-9 Procedure Codes 0044 PROC-VESSEL BIFURCATION OCT06- 0201 LINEAR CRANIECTOMY 0050 IMPL CRT PACEMAKER SYS 0202 ELEVATE SKULL FX FRAGMNT 0051 IMPL CRT DEFIBRILLAT SYS 0203 SKULL FLAP FORMATION 0052 IMP/REP LEAD LF VEN SYS 0204 BONE GRAFT TO SKULL 0053 IMP/REP CRT PACEMAKR GEN 0205 SKULL PLATE INSERTION 0054 IMP/REP CRT DEFIB GENAT 0206 CRANIAL OSTEOPLASTY NEC 0056 INS/REP IMPL SENSOR LEAD OCT06- 0207 SKULL PLATE REMOVAL 0057 IMP/REP SUBCUE CARD DEV OCT06- 0211 SIMPLE SUTURE OF DURA 0061 PERC ANGIO PRECEREB VES (OCT 04) 0212 BRAIN MENINGE REPAIR NEC 0062 PERC ANGIO INTRACRAN VES (OCT 04) 0213 MENINGE VESSEL LIGATION 0066 PTCA OR CORONARY ATHER OCT05- 0214 CHOROID PLEXECTOMY 0070 REV HIP REPL-ACETAB/FEM OCT05- 022 VENTRICULOSTOMY 0071 REV HIP REPL-ACETAB COMP OCT05- 0231 VENTRICL SHUNT-HEAD/NECK 0072 REV HIP REPL-FEM COMP OCT05- 0232 VENTRI SHUNT-CIRCULA SYS 0073 REV HIP REPL-LINER/HEAD OCT05- 0233 VENTRICL SHUNT-THORAX 0074 HIP REPL SURF-METAL/POLY OCT05- 0234 VENTRICL SHUNT-ABDOMEN 0075 HIP REP SURF-METAL/METAL OCT05- 0235 VENTRI SHUNT-UNINARY SYS 0076 HIP REP SURF-CERMC/CERMC OCT05- 0239 OTHER VENTRICULAR SHUNT 0077 HIP REPL SURF-CERMC/POLY OCT06- 0242 REPLACE VENTRICLE SHUNT 0080 REV KNEE REPLACEMT-TOTAL OCT05- 0243 REMOVE VENTRICLE SHUNT 0081 REV KNEE REPL-TIBIA COMP OCT05- 0291 LYSIS CORTICAL ADHESION 0082 REV KNEE REPL-FEMUR COMP OCT05- 0292 BRAIN REPAIR 0083 REV KNEE REPLACE-PATELLA OCT05- 0293 IMPLANT BRAIN STIMULATOR 0084 REV KNEE REPL-TIBIA LIN OCT05- 0294 INSERT/REPLAC SKULL TONG 0085 RESRF HIPTOTAL-ACET/FEM -
Ipo) List for Cy 2021 (N=266)
TABLE 31: PROPOSED MUSCULOSKELETAL-RELATED SERVICE REMOVALS FROM THE INPATIENT ONLY (IPO) LIST FOR CY 2021 (N=266) CY CY 2020 Long Descriptor Related Proposed Proposed 2020 Services CY 2021 CY 2021 CPT OPPS OPPS APC Code Status Assignment Indicator 0095T Removal of total disc arthroplasty 22856 N/A (artificial disc), anterior approach, each additional interspace, cervical (list separately in addition to code for primary procedure) 0098T Revision including replacement 22858 N/A of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (list separately in addition to code for primary procedure) 0163T Total disc arthroplasty (artificial 22858 N/A disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (list separately in addition to code for primary procedure) 0164T Removal of total disc 22856 N/A arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (list separately in addition to code for primary procedure) 0165T Revision including replacement 22858 N/A of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (list separately in addition to code for primary procedure) 0202T Posterior vertebral joint(s) 63030 J1 5115 arthroplasty (for example, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine -
Summary of Services and Availability (By Location)
UPMC | University of Pittsburgh Medical Center For Reference Only UROLOGY 2013 Summary of Services and Availability (by location) Each location has sufficient space, equipment, staffing and financial resources in place or available in sufficient time as required to support each requested privilege. On an ongoing basis, the organization consistently determines the resources necessary for each requested privilege related to the facility's scope of service. Please review the following Summary of Services and Availability by Location prior to making your selections. If a facility is specifically identified below as NOT having a privilege/service available, you will NOT be considered for that privilege at that individual facility. Any request made that is identified as not available at an individual site will be considered Not Applicable for that site(s), and will be identified as such on your final approved Delineation of Privileges form. “x” means Privilege is Available at that location. “C” means contractual arrangement restricts granting this privilege. “N/A” means Privilege Not Available at that location. Facility Codes: UHOC= UPMC St. Margaret Harmar Outpatient Center Privilege UHOC Core privileges X Consultation Privileges N/A SURGERY OF THE KIDNEY, ADRENAL, URETER, AND BLADDER Biopsy, all techniques X Nephrotomy/pyelotomy/ureterotomy/ cystotomy for X stent placement, stone extraction, drainage abscess, biopsy, fulgeration, insertion of radioactive material Percutaneous nephroscopy, and other percutaneous X catheter techniques Nephrectomy, -
Laparoscopic Ureterolysis Without Omentoplasty in the Management of the Uropathy Secondary to Idiopathic Retroperitoneal Fibrosi
CASE REPORT Laparoscopic Ureterolysis without Omentoplasty in the Management of the Uropathy Secondary to Idiopathic Retroperitoneal Fibrosis Miguel A Bergero1, Patricio A Garcia Marchiñena2, Guillermo Gueglio3, Carlos David4, Fernando Dipatto5, Alberto Jurado6 ABSTRACT Introduction: Obstructive uropathy (OU) secondary to idiopathic retroperitoneal fibrosis (IRF) is an infrequent disease, and the standard treatment has not been established. However, ureterolysis with ureteral intraperitonealization is an effective therapeutic alternative. We present the successful management of OU secondary to an IRF by laparoscopic ureterolysis without omentoplasty (LUWO). Materials and methods: A retrospective descriptive study of 5 patients with IRF treated with LUWO was performed. Results: The average age was 60.4 years. The average creatinine was 3.86 mg/dL. There were no intraoperative or major postoperative complications. In a follow-up period of 31.2 months, all patients are asymptomatic, with an average creatinine level of 1.52 without dialysis requirement. No patients required corticosteroid therapy after surgery. Conclusion: Laparoscopic ureterolysis without omentoplasty is a safe and feasible option to treat the OU caused by IRF that provides good results in the medium-term follow-up, as we describe it in our series of cases. Keywords: Hydronephrosis, Laparoscopy, Retroperitoneal fibrosis, Ureteral obstruction. World Journal of Laparoscopic Surgery (2019): 10.5005/jp-journals-10033-1377 INTRODUCTION 1,4,5Department of Urology, Sanatorio Privado San Geronimo, Santa Fe, Obstructive uropathy (OU) related to idiopathic retroperitoneal Argentina fibrosis (IRF) is a rare disease characterized by retroperitoneal 2,3,6Department of Urology, Hospital Italiano de Buenos Aires, Buenos fibrosis. The pathology has theorized to be an inflammatory Aires, Argentina response to oxidized low-density lipoproteins.1,2 Because IRF has Corresponding Author: Miguel A Bergero, Department of Urology, 3–5 a very low prevalence, no treatments have been standardized.